Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors
- PMID: 15265488
- DOI: 10.1016/j.bmc.2004.06.019
Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors
Abstract
In a recent preliminary communication we described the development of a series of hybrid molecules for the dopamine D2 and D3 receptor subtypes. The design of these compounds was based on combining pharmacophoric elements of aminotetralin and piperazine molecular fragments derived from known dopamine receptor agonist and antagonist molecules. Molecules developed from this approach exhibited high affinity and selectivity for the D3 receptor as judged from preliminary [(3)H]spiperone binding data. In this report, we have expanded our previous finding by developing additional novel molecules and additionally evaluated functional activities of these novel molecules in the [(3)H]thymidine incorporation mitogenesis assay. The binding results indicated highest selectivity in the bioisosteric benzothiazole derivative N6-[2-(4-phenyl-piperazin-1-yl)-ethyl]-N6-propyl-4,5,6,7-tetrahydro-benzothiazole-2,6-diamine (14) for the D3 receptor whereas the racemic compound 7-([2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl]-propyl-amino)-5,6,7,8-tetrahydro-naphthalen-2-ol (10c) showed the strongest potency. Mitogenesis studies to evaluate functional activity demonstrated potent agonist properties in these novel derivatives for both D2 and D3 receptors. In this regard, compound 7-[[4-(4-phenyl-piperazin-1-yl)-butyl]-prop-2-ynyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol (7b) exhibited the most potent agonist activity at the D3 receptor, 10 times more potent than quinpirole and was also the most selective compound for the D3 receptor in this series. Racemic compound 10a was resolved; however, little separation of activity was found between the two enantiomers of 10a. The marginally more active enantiomer (-)-10a was examined in vivo using the 6-OH-DA induced unilaterally lesioned rat model to evaluate its activity in producing contralateral rotations. The results demonstrated that in comparison to the reference compound apomorphine, (-)-10a was quite potent in inducing contralateral rotations and exhibited longer duration of action.
Similar articles
-
Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor.Bioorg Med Chem. 2009 Jun 1;17(11):3923-33. doi: 10.1016/j.bmc.2009.04.031. Epub 2009 Apr 19. Bioorg Med Chem. 2009. PMID: 19427222 Free PMC article.
-
Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.J Med Chem. 2005 Feb 10;48(3):839-48. doi: 10.1021/jm049465g. J Med Chem. 2005. PMID: 15689168
-
Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors.Bioorg Med Chem. 2013 Jun 1;21(11):3164-74. doi: 10.1016/j.bmc.2013.03.059. Epub 2013 Apr 1. Bioorg Med Chem. 2013. PMID: 23623679 Free PMC article.
-
Dopamine D3 receptor ligands with antagonist properties.Chembiochem. 2002 Oct 4;3(10):946-61. doi: 10.1002/1439-7633(20021004)3:10<946::AID-CBIC946>3.0.CO;2-5. Chembiochem. 2002. PMID: 12362359 Review.
-
Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates.Trends Pharmacol Sci. 2011 Mar;32(3):148-57. doi: 10.1016/j.tips.2010.12.003. Epub 2011 Jan 12. Trends Pharmacol Sci. 2011. PMID: 21232805 Review.
Cited by
-
Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor.Bioorg Med Chem. 2009 Jun 1;17(11):3923-33. doi: 10.1016/j.bmc.2009.04.031. Epub 2009 Apr 19. Bioorg Med Chem. 2009. PMID: 19427222 Free PMC article.
-
Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization.J Med Chem. 2012 Jun 28;55(12):5826-40. doi: 10.1021/jm300268s. Epub 2012 Jun 13. J Med Chem. 2012. PMID: 22642365 Free PMC article.
-
Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.Cell Signal. 2018 Jan;41:75-81. doi: 10.1016/j.cellsig.2017.07.003. Epub 2017 Jul 14. Cell Signal. 2018. PMID: 28716664 Free PMC article. Review.
-
Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease.J Med Chem. 2010 Mar 11;53(5):2114-25. doi: 10.1021/jm901618d. J Med Chem. 2010. PMID: 20146482 Free PMC article.
-
Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.Bioorg Med Chem. 2016 Aug 15;24(16):3464-71. doi: 10.1016/j.bmc.2016.05.053. Epub 2016 May 27. Bioorg Med Chem. 2016. PMID: 27312422 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources